People

Guillaume Froget is Senior Advisor to Porsolt following Xavier Morge’s2025 appointment as President. He previously led Porsolt as President and CEO and was named in its2015 Fluofarma acquisition and2023 majority-buyout announcements. He has contributed to preclinical pharmacology and oncology research and represented Porsolt in the2022 GPS collaboration on patient-derived glioblastoma models. His former executive titles are historical; current adviser status is explicitly sourced.